Company Overview
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company markets UltraMist system, a medical device that uses non-thermal ultrasound to treat tissues using a fluid mist to transmit energy in a non-contact and pain free way for use in the treatment of acute and chronic wounds. The company was founded in 2004 and is headquartered in Eden Prairie, Minnesota.
Why Investors Should Care
Return on capital employed stands at 25.4%.
Revenue has grown at a 31.4% CAGR over the past five years.
Trades at a P/E of 7.6, below the sector median of 25.9.
Maintains a net profit margin of 37.2%.
Recent Developments
- Dec 2025 Revenue of $44.05M (+36.3% YoY); net profit $11.81M.
- Trailing 12 Months Year-on-year growth — revenue +3.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 31.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 31.45% |
| 1 Year: | 3.10% |
Stock Price Performance
| 1 Year: | -79.89% |
| 6 Months: | -75.24% |
| 3 Months: | -58.48% |
| 1 Month: | -51.24% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.44 · Neutral
P/E of 7.57 is below the sector median of 25.88 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 25.4%.
- Excellent profit margin of 37.2%.
- Compounding revenue at 31.4% over 5 years.
CONS
- Trading 83.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SNWV SANUWAVE Health, Inc. R2K | 7.27 | 7.57 | $62.51M | 0.00% | 25.36% | - | 31.45% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 197.64K | 149.00K | 83.00K | 1.37M | 1.86M | 2.63M | 3.73M | 2.85M | 3.54M | 3.92M | 3.49M | 4.41M | 4.82M | 5.68M | 7.08M | 9.29M | 9.29M | 10.15M | 11.42M | - |
| Gross Profit | 145.42K | 136.83K | 118.95K | 126.76K | 174.72K | 159.41K | 151.63K | 164.20K | 104.85K | 196.14K | 125.42K | 156.97K | - | - | 99.90K | 178.81K | 286.57K | 412.19K | 84.11K | 131.09K | 74.72K | 19.00K | 4.00K | 765.00K | 1.06M | 1.86M | 2.17M | 2.31M | 2.79M | 3.01M | 2.51M | 3.47M | 3.54M | 4.20M | 5.24M | 7.07M | 7.38M | 7.85M | 8.74M | 7.43M |
| Operating Income | -1.13M | -1.73M | -1.89M | -2.02M | -1.61M | -1.41M | -1.13M | -1.01M | -1.32M | -689.47K | -1.02M | -833.61K | -620.64K | -1.31M | -647.78K | -1.12M | -2.12M | -2.67M | -1.86M | -2.02M | -2.39M | -2.80M | -3.27M | -6.37M | -4.39M | -4.05M | -3.33M | -1.96M | -3.05M | -2.48M | -1.98M | 931.00K | -531.00K | -1.29M | 1.65M | 1.48M | 601.00K | 1.44M | 903.00K | -1.12M |
| Net Income | -5.37M | -818.33K | -4.44M | -2.56M | -1.69M | -1.49M | -1.16M | -1.52M | -1.03M | -1.72M | -1.12M | -1.14M | -493.53K | -1.42M | -851.33K | -5.86M | -2.89M | -825.14K | -2.20M | -2.73M | -2.75M | -3.00M | -3.63M | -12.64M | -4.94M | -8.62M | -4.25M | -5.10M | 1.64M | -1.14M | -13.08M | -7.26M | -23.70M | -4.80M | 6.19M | -21.16M | -6.12M | 551.00K | 9.69M | -1.44M |
| Diluted EPS | -0.25 | -0.04 | -0.14 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.01 | -0.01 | -0.03 | -0.01 | -0.02 | -0.01 | -0.01 | 0.00 | 0.00 | -0.02 | -0.01 | -9.95 | 0.00 | 0.00 | -6.65 | -0.72 | -0.04 | 0.39 | -0.17 |
| R&D Expense | 344.69K | 624.53K | 775.72K | 764.85K | 1.01M | 708.30K | 634.62K | 456.79K | 569.13K | 309.95K | 476.17K | 266.47K | 260.34K | 437.91K | 266.84K | 238.48K | 328.75K | 622.15K | 261.00K | 307.27K | 299.90K | 287.00K | 265.00K | 432.00K | 354.00K | 272.00K | 297.00K | 166.00K | 171.00K | 157.00K | 131.00K | 139.00K | 165.00K | 163.00K | 195.00K | 161.00K | 208.00K | 194.00K | 345.00K | 660.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 728.45K | 802.57K | 769.22K | 800.03K | 847.37K | 965.50K | 1.38M | 738.53K | 1.85M | 1.03M | 3.63M | 11.38M | 15.51M | 19.25M | 32.33M | 44.05M |
| Gross Profit | 478.12K | 540.68K | 548.96K | 610.24K | 627.39K | 680.54K | - | 496.56K | 1.16M | 489.81K | 2.90M | 8.02M | 12.41M | 14.36M | 24.55M | 33.97M |
| Operating Income | -11.81M | -8.81M | -6.06M | -5.98M | -5.96M | -4.44M | -3.32M | -3.82M | -7.18M | -8.79M | -25.20M | -14.14M | -8.95M | -540.00K | 3.85M | 4.95M |
| Net Income | -14.92M | -10.24M | -6.40M | -11.30M | -5.97M | -4.81M | -6.44M | -5.54M | -11.63M | -10.43M | -30.94M | -27.26M | -10.29M | -25.81M | -33.08M | 11.81M |
| Diluted EPS | -1.15 | -0.52 | -0.30 | - | - | - | - | - | - | -0.05 | -0.08 | -0.05 | -0.02 | -12.19 | -7.41 | 0.41 |
| R&D Expense | 3.88M | 2.73M | 1.76M | 2.30M | 3.00M | 2.17M | 1.13M | 1.29M | 981.65K | 1.18M | 1.25M | 1.10M | 567.00K | 579.00K | 673.00K | 1.35M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Dec 2023 | Jan 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 3.03M | 6.17M | 1.85M | 1.59M | 4.67M | 958.36K | 1.00M | 1.28M | 1.18M | 3.38M | 23.03M | 18.62M | 17.01M | 17.84M | 18.78M | 19.87M | 22.42M | - | 30.12M | - | - | - | 37.34M |
| Total Equity | - | -10.52M | -1.54M | -6.52M | -6.13M | -1.55M | -5.88M | -6.91M | -9.88M | -15.36M | -10.06M | -13.72M | -38.96M | -38.07M | -35.53M | -35.31M | -41.01M | -44.55M | -44.55M | -15.79M | -20.81M | -18.80M | -7.59M | 1.62M |
| Cash & Equivalents | 1.79M | 417.46K | 3.91M | 70.33K | 182.31K | 3.55M | 152.93K | 133.57K | 730.18K | 364.55K | 1.76M | 2.44M | 619.00K | 313.00K | 1.48M | 1.11M | 1.15M | 1.80M | - | 10.24M | - | - | - | 11.96M |
| Long Term Debt | - | - | - | 5.37M | - | - | - | 5.37M | - | - | - | 143.00K | 875.00K | - | - | - | - | - | - | - | - | - | - | 16.14M |
| Total Liabilities | - | 13.55M | 7.70M | 8.37M | 7.72M | 6.22M | 6.84M | 7.92M | 11.16M | 16.53M | 13.45M | 36.74M | 57.58M | 55.08M | 53.38M | 54.09M | 60.88M | 65.59M | 66.96M | 45.91M | 51.67M | 51.84M | 43.19M | 35.72M |
| Current Liabilities | - | 8.17M | 2.32M | 2.99M | 2.34M | 6.22M | 1.49M | 7.92M | 11.16M | 16.49M | 12.42M | 36.17M | 56.26M | 53.91M | 52.25M | 53.59M | 60.22M | 64.75M | - | 45.42M | 50.78M | 50.42M | 23.98M | 17.85M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.87M | -8.83M | -4.29M | -3.92M | -6.68M | -3.47M | -3.20M | -1.53M | -3.62M | -6.41M | -12.72M | -6.41M | -17.17M | -4.54M | 2.46M | 3.88M |
| Investing Cash Flow | 7.00K | -42.30K | -2.01K | 7.50K | -8.86K | 100.00K | -8.77K | 0 | -42.89K | -53.94K | -20.05M | -529.00K | 332.00K | 21.00K | -490.00K | 3.43M |
| Financing Cash Flow | 4.50M | 12.37M | 450.42K | 4.04M | 10.07M | - | 3.21M | 2.12M | 3.32M | 7.86M | 33.45M | 5.12M | 17.38M | 5.21M | 6.35M | -5.59M |
| Capital Expenditure | - | -42.30K | -2.01K | - | -8.86K | - | -10.36K | -0 | -42.89K | -53.94K | -53.00K | -529.00K | - | -0 | -490.00K | -1.94M |
| Free Cash Flow | - | -8.87M | -4.29M | - | -6.69M | - | -3.21M | -1.53M | -3.66M | -6.46M | -12.77M | -6.94M | - | -4.54M | 1.97M | 1.93M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 65.6% | 67.4% | 71.4% | 76.3% | 74.0% | 70.5% | - | 67.2% | 62.5% | 47.6% | 79.8% | 70.5% | 80.0% | 74.6% | 75.9% | 77.1% |
| Operating Margin % | -1,620.9% | -1,097.6% | -788.1% | -747.0% | -703.8% | -459.6% | -241.0% | -517.8% | -388.1% | -854.9% | -694.6% | -124.2% | -57.7% | -2.8% | 11.9% | 11.2% |
| Net Margin % | -2,048.5% | -1,275.7% | -832.2% | -1,412.4% | -705.0% | -498.2% | -467.9% | -749.9% | -628.7% | -1,013.9% | -852.7% | -239.5% | -66.4% | -134.0% | -102.3% | 26.8% |
| ROE % | 141.9% | 666.4% | 98.2% | 184.4% | 385.1% | 81.8% | 93.2% | 56.0% | 75.7% | 103.6% | 225.5% | 70.0% | 25.1% | 57.9% | 209.5% | 729.6% |
| ROCE % | 229.6% | -229.1% | 530.7% | 791.4% | 384.4% | 837.8% | 48.0% | 38.7% | 46.9% | 97.4% | 191.7% | 37.6% | 22.2% | 1.3% | -25.1% | 25.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Opaleye Management Inc. | 11.48% | 981.27K | $7.30M |
| 2 | Blackrock Inc. | 5.63% | 481.54K | $3.58M |
| 3 | AWM Investment Company, Inc. | 5.32% | 454.55K | $3.38M |
| 4 | Praetorian PR LLC | 4.10% | 350.00K | $2.60M |
| 5 | Vanguard Capital Management LLC | 4.08% | 348.87K | $2.60M |
| 6 | Solas Capital Management, LLC | 3.36% | 287.51K | $2.14M |
| 7 | Stifel Financial Corporation | 2.94% | 251.63K | $1.87M |
| 8 | UBS Group AG | 2.46% | 210.26K | $1.56M |
| 9 | Geode Capital Management, LLC | 2.01% | 171.80K | $1.28M |
| 10 | State Street Corporation | 1.64% | 140.09K | $1.04M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SNWV
Ultramist consumable applicator sales set all-time records in Sanuwave’s Q2 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQZzd6bFRIaVNHMzdhVzN6b1kyRGt2TEh6djBfYlI2OHc0UHpqY013V1ZkSUNWQ0RkQjUzLWFhdWNWTEdEOUlwZ203bGcteHQxMDEyLW9RbmVwZHJudEdnSWtuSEREb29kOGYyZVp4Z0t1SzZGb3l3YXFyVHJrQVVfVms2SkhuQVVFTGpKaG…
Sanuwave Health Reports Preliminary Second Quarter 2026 Revenue Above Revised Guidance Range - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNdll5cXhZaFR5bTBobG5HbFBCWVM0aDhrRktUb3BTeUE0ODJFTGtlb29MMTdZQXFWVGdrVXdlbjI5Qy1Mb0x4ZDVTanpGbS1aUHlaNWN3dklMdmxmZ0tqOXhsQWZXbjZVTmhRU1Q0UDc4QjlKaWxJZE1IanVac3lBcUw5SzBPb0VrNkJYMD…
Sanuwave Health (SNWV) Raises Q2 Revenue Expectations to $9.6M-$9.8M - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiogJBVV95cUxPejBialdpLWdRWGtEVkRkOFA1ZXpOdXlDaUZPbGRaNFFOcHAyYW81Ny1GaWhZdXluOWN3NDR5c0N6OEdlMEJyaGtqUmZHeDh6clA3YTd4UFhFSmxMRTYydFZ4MVJnTEx3d0FyQVZ1SGUySWdrTVkybHNzbEg1RHZtSTNUcDNnTmFhSjJmUl…
SANUWAVE Health (NASDAQ:SNWV) investors are sitting on a loss of 63% if they invested five years ago - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNNzN0VXhkQlh5ZVVKWWYwT1V5QnE3bkc4TzdBZ2RsMlN0MzRBY2hfVjFTbU9CdE12TzIyQkowWmZOMjVDa3B5SlNKWHNmaEJ4emUzenFEQ01yb1VNTmxVOE5PVU5oUkYxNEx4R2g0cFUtMXFLby1iMmc0N1dSbzB3dlFsVExpOEtOOU5N?o…
Shareholders Shouldn’t Be Too Comfortable With SANUWAVE Health's (NASDAQ:SNWV) Strong Earnings - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxNR1dFZEZjaDB5MnltcGEydG5HMU14VGdqUTZFMTNmQmFCZEdrdGtxellSbW1pNzZZNVFiLTFnUHVjR1NoSUhJaU9Zd2x1bEVPODI0RWI1STBWTzJfVFNrdHRnRmZrR3BYU3dfQ3BRQlpGdW50VktHb2loN0JWOXBOaGt6S3VOa0UzTk5NTj…
$SNWV stock is up 17% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOUFZidkpWMDRWeU9ZRmFFaTlNVFpYSjBQbThISnVDQ3lCRUM2YzczdTU0YUtUYnYyU1piT1ZlNlMxV040Qmh1UkswUl9lamFjU0N0TlZGZ3BMYzctMzBOSjR0VzhHSWNyT2t2WVlYWnQ1MTJFNDJKQlZfdk5NQnhUUmRZYkhRQXlZUGxGNj…
SNWV — Frequently Asked Questions
What is the current share price of SANUWAVE Health, Inc. (SNWV)?
As of 2026-07-15 16:51 PDT, SANUWAVE Health, Inc. (SNWV) trades at $7.27 on NasdaqGM. Its 52-week range is $7.27 to $45.00.
What is the market capitalisation of SNWV?
SANUWAVE Health, Inc. (SNWV) has a market capitalisation of $62.51M on NasdaqGM.
What is the P/E ratio of SNWV?
SNWV trades at a trailing price-to-earnings (P/E) ratio of 7.57. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 34.77.
Is SNWV a good stock to buy?
This page provides a data-driven analysis of SANUWAVE Health, Inc. (SNWV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.